Search

Your search keyword '"Wijatyk, Anna"' showing total 26 results
Start Over Author "Wijatyk, Anna"
Sorry, I don't understand your search. ×
26 results on '"Wijatyk, Anna"'

1. P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY

Author

Shah, Nirav, primary, Maziarz, Richard, additional, Jacobson, Caron, additional, Isufi, Iris, additional, Ghosh, Monalisa, additional, Ulrickson, Matthew, additional, Perales, Miguel-Angel, additional, Lunning, Matthew, additional, Hardy, Nancy, additional, Wijatyk, Anna, additional, Ancukiewicz, Marek, additional, Nallewar, Madhavi, additional, Coleman, Kimberly, additional, Prudner, Bethany, additional, Eromosele, Esther, additional, Kaleta, Remigiusz, additional, and Miklos, David, additional

Published
2023
Full Text
View/download PDF

2. Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa

Author

Goker-Alpan, Ozlem, Nedd, Khan, Shankar, Suma P., Lien, Yeong-Hau H., Weinreb, Neal, Wijatyk, Anna, Chang, Peter, Martin, Rick, Zschocke, Johannes, Editor-in-chief, Baumgartner, Matthias, editor, Morava, Eva, editor, Patterson, Marc, editor, Rahman, Shamima, editor, and Peters, Verena, editor

Published
2015
Full Text
View/download PDF

3. Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)

Author

Shah, Nirav N., primary, Maziarz, Richard T, additional, Jacobson, Caron A., additional, Ghosh, Monalisa, additional, Isufi, Iris, additional, Ulrickson, Matthew L., additional, Perales, Miguel-Angel, additional, Lunning, Matthew, additional, Hardy, Dr. Nancy Maureen, additional, Wijatyk, Anna, additional, Ancukiewicz, Marek, additional, Nallewar, Mrs. Madhavi, additional, Coleman, Kimberly C., additional, Prudner, Bethany, additional, Eromosele, Esther, additional, Kaleta, Remi, additional, and Miklos, David B., additional

Published
2023
Full Text
View/download PDF

5. Abstract 1677: Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimab

Author

Shapiro, Irina, primary, Lim, Min, additional, Pabla, Simarjot, additional, O'Day, Steven J., additional, El-Khoueiry, Anthony, additional, Ramamurthy, Chethan, additional, Bullock, Andrea J., additional, Gordon, Michael S., additional, Buell, Jennifer, additional, Chand, Dhan, additional, and Wijatyk, Anna, additional

Published
2021
Full Text
View/download PDF

6. 267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer

Author

O’Malley, David, primary, Feliu, Waldo Ortuzar, additional, Ray-Coquard, Isabelle, additional, O’Neal, Michael, additional, Alexandre, Jerome, additional, Cole, Julie, additional, Ludwig, Robert, additional, Nallewar, Madhavi, additional, Buell, Jennifer, additional, Kaleta, Remigiusz, additional, Wijatyk, Anna, additional, and Borisovskaya, Victoria, additional

Published
2020
Full Text
View/download PDF

7. 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Author

Galand, Claire, primary, Venkatraman, Vignesh, additional, Marques, Marilyn, additional, Strauss, James, additional, Carvajal, Richard, additional, Lim, Min, additional, Morin, Benjamin, additional, Ignatovich, Olga, additional, Findeis, Mark, additional, Underwood, Dennis, additional, Dijk, Marc Van, additional, Shapiro, Irina, additional, Ohanjanian, Lernik, additional, Wijatyk, Anna, additional, Wilson, Nicholas, additional, Buell, Jennifer, additional, Chand, Dhan, additional, Savitsky, David, additional, and Tolcher, Anthony, additional

Published
2020
Full Text
View/download PDF

9. 16 - Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)

Author

Shah, Nirav N., Maziarz, Richard T, Jacobson, Caron A., Ghosh, Monalisa, Isufi, Iris, Ulrickson, Matthew L., Perales, Miguel-Angel, Lunning, Matthew, Hardy, Dr. Nancy Maureen, Wijatyk, Anna, Ancukiewicz, Marek, Nallewar, Mrs. Madhavi, Coleman, Kimberly C., Prudner, Bethany, Eromosele, Esther, Kaleta, Remi, and Miklos, David B.

Published
2023
Full Text
View/download PDF

10. AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.

Author

O'Day, Steven, primary, Ramamurthy, Chethan, additional, Bullock, Andrea J., additional, El-Khoueiry, Anthony B., additional, Ohanjanian, Lernik, additional, Wijatyk, Anna, additional, Ortuzar Feliu, Waldo Ignacio, additional, Shapiro, Irina, additional, Ancukiewicz, Marek, additional, Chand, Dhan, additional, Buell, Jennifer, additional, and Gordon, Michael S., additional

Published
2020
Full Text
View/download PDF

12. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

Author

Papanicolaou, Genovefa A, primary, Silveira, Fernanda P, additional, Langston, Amelia A, additional, Pereira, Marcus R, additional, Avery, Robin K, additional, Uknis, Marc, additional, Wijatyk, Anna, additional, Wu, Jingyang, additional, Boeckh, Michael, additional, Marty, Francisco M, additional, and Villano, Stephen, additional

Published
2018
Full Text
View/download PDF

13. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Author

Beck, Michael, Hughes, Derralynn, Kampmann, Christoph, Larroque, Sylvain, Mehta, Atul, Pintos-Morellell, Guillem, Ramaswami, Uma, West, Michael, Wijatyk, Anna, Giugliani, Roberto, and Universitat Autònoma de Barcelona

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Urology, Cardiomyopathy, Renal function, SE, Standard error, Left ventricular hypertrophy, Biochemistry, LVH, Left ventricular hypertrophy, Long-term effectiveness, Endocrinology, Genetics, Medicine, MDRD, Modification of Diet in Renal Disease, lcsh:QH301-705.5, Molecular Biology, Agalsidase alfa, eGFR, Estimated glomerular filtration rate, Fabry disease, lcsh:R5-920, CI, Confidence interval, business.industry, Enzyme replacement therapy, medicine.disease, Egfr, Estimated glomerular filtration rate, Surgery, ARB, Angiotensin receptor blocker, SEM, Standard error of the mean, Standard error, lcsh:Biology (General), SI:Therapy, Cohort, FOS, Fabry Outcome Survey, LVMI, Left ventricular mass indexed to height, lcsh:Medicine (General), business, ACEI, Angiotensin-converting enzyme inhibitor, ERT, Enzyme replacement therapy
Abstract

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no treatment, patients treated with agalsidase alfa demonstrated slower decline in renal function and slower progression of left ventricular hypertrophy. Treated male patients with baseline eGFR < 60 mL/min/1.73 m 2 had a mean (standard error of the mean [SEM]) annualized change in eGFR of − 2.86 (0.53) mL/min/1.73 m 2 /y compared with − 6.8 (1.5) in the published untreated cohort. The mean (SEM) rate of LVMI increase with treatment was 0.33 (0.10) g/m 2.7 /y in males and 0.48 (0.09) in females, compared with 4.07 (1.03) in untreated males and 2.31 (0.81) in untreated females. Morbidity occurred later in treated patients, with ~ 16% risk of a composite morbidity event (26% in males) after 24 months with ERT versus ~ 45% without treatment, with first events and deaths also occurring at older ages in patients administered ERT (e.g., estimated median survival in treated males was 77.5 years versus 60 years in untreated males). Findings from these retrospective comparisons of observational data and published literature support the long-term benefits of ERT with agalsidase alfa for Fabry disease in slowing the progression of renal impairment and cardiomyopathy. Treatment also appeared to delay the onset of morbidity and mortality. Interpretation of these findings should take into account that they are based on retrospective comparisons with previously published data.

Published
2015

14. Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study

Author

Papanicolaou, Genovefa A., primary, Silveira, Fernanda P., additional, Langston, Amelia A., additional, Pereira, Marcus R., additional, Avery, Robin K., additional, Wijatyk, Anna, additional, Wu, Jingyang J., additional, Boeckh, Michael J., additional, Marty, Francisco M., additional, and Villano, Stephen, additional

Published
2017
Full Text
View/download PDF

15. Maribavir Versus Valganciclovir for Pre-Emptive Treatment of Cytomegalovirus Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients

Author

Maertens, Johan A., primary, Cordonnier, Catherine, additional, Jaksch, Peter, additional, Poiré, Xavier, additional, Wu, Jingyang J., additional, Wijatyk, Anna, additional, Saliba, Faouzi, additional, Witzke, Oliver, additional, and Villano, Stephen, additional

Published
2017
Full Text
View/download PDF

16. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.

Author

Papanicolaou, Genovefa A, Silveira, Fernanda P, Langston, Amelia A, Pereira, Marcus R, Avery, Robin K, Uknis, Marc, Wijatyk, Anna, Wu, Jingyang, Boeckh, Michael, Marty, Francisco M, and Villano, Stephen

Subjects
ANTIVIRAL agents, CYTOMEGALOVIRUS diseases, DNA, DRUG resistance, HEMATOPOIETIC stem cell transplantation, GENETIC mutation, NEUTROPHILS, NUCLEOSIDES, TASTE disorders, TIME, TRANSPLANTATION of organs, tissues, etc., RANDOMIZED controlled trials, TREATMENT effectiveness, ADVERSE health care events, DESCRIPTIVE statistics, THERAPEUTICS
Abstract

Background Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains. Methods Hematopoietic-cell or solid-organ transplant recipients ≥12 years old with RR CMV infections and plasma CMV deoxyribonucleic acid (DNA) ≥1000 copies/mL were randomized (1:1:1) to twice-daily dose-blinded maribavir 400, 800, or 1200 mg for up to 24 weeks. The primary efficacy endpoint was the proportion of patients with confirmed undetectable plasma CMV DNA within 6 weeks of treatment. Safety analyses included the frequency and severity of treatment-emergent adverse events (TEAEs). Results From July 2012 to December 2014, 120 patients were randomized and treated (40 per dose group): 80/120 (67%) patients achieved undetectable CMV DNA within 6 weeks of treatment (95% confidence interval, 57–75%), with rates of 70%, 63%, and 68%, respectively, for maribavir 400, 800, and 1200 mg twice daily. Recurrent on-treatment CMV infections occurred in 25 patients; 13 developed mutations conferring maribavir resistance. Maribavir was discontinued due to adverse events in 41/120 (34%) patients, and 17/41 discontinued due to CMV infections. During the study, 32 (27%) patients died, 4 due to CMV disease. Dysgeusia was the most common TEAE (78/120; 65%) and led to maribavir discontinuation in 1 patient. Absolute neutrophil counts <1000/µL were noted in 12/106 (11%) evaluable patients, with rates similar across doses. Conclusions Maribavir ≥400 mg twice daily was active against RR CMV infections in transplant recipients; no new safety signals were identified. Clinical Trials Registration NCT01611974. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study

Author

Papanicolaou, Genovefa, primary, Silveira, Fernanda P., additional, Langston, Amelia, additional, Pereira, Marcus R., additional, Avery, Robin, additional, Wijatyk, Anna, additional, Wu, Jingyang J, additional, Boeckh, Michael, additional, Marty, Francisco M., additional, and Villano, Stephen, additional

Published
2016
Full Text
View/download PDF

19. Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients

Author

Maertens, Johan, primary, Cordonnier, Catherine, additional, Jaksch, Peter, additional, Poiré, Xavier, additional, Wu, Jingyang J, additional, Wijatyk, Anna, additional, Saliba, Faouzi, additional, Witzke, Oliver, additional, and Villano, Stephen, additional

Published
2016
Full Text
View/download PDF

20. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Author

Goláň, Lubor, primary, Goker-Alpan, Ozlem, additional, Holida, Myrl, additional, Kantola, Ikka, additional, Klopotowski, Mariusz, additional, Kuusisto, Johanna, additional, Linhart, Aleš, additional, Musial, Jacek, additional, Nicholls, Kathleen, additional, Gonzalez Rodríguez, Derlis, additional, Sharma, Reena, additional, Vujkovac, Bojan, additional, Chang, Peter, additional, and Wijatyk, Anna, additional

Published
2015
Full Text
View/download PDF

24. Agalsidase alfa in pediatric patients with Fabry disease: A 7-year open-label study

Author

Chang Peter, Wijatyk Anna, Gregory M. Pastores, Martin Rick, and Raphael Schiffmann

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, medicine.disease, Biochemistry, Fabry disease, Endocrinology, Open label study, Genetics, Medicine, business, Molecular Biology, Agalsidase alfa
Published
2013

26. An efficient method for the synthesis of 6,7-bis(alkylthio-or alkylamino-substituted) quinoline-5,8-diones via nucleophilic addition/oxidation of alkylthio and alkylamino derivatives to quinoline-5,8-dione.

Author

Odens, Herman H., Silva, Trevor S., Olusola, Candace N., Odens Jr., Herman H., Howe, Victoria A., and Wijatyk, Anna I.

Subjects
*CHEMICAL synthesis, *GROUP rings, *OXIDATION, *ACETONITRILE, *NUCLEOPHILES
Abstract

A new variety of 6,7-bis(alkylthio-or alkylamino-substituted)quinoline-5,8-diones were prepared by the addition of mercaptans or amino nucleophiles to quinoline-5,8-dione after subsequent oxidation with NaIO4. The core quinoline-5,8-dione intermediate was prepared from the oxidation of 5-quinolinol or 8-quinolinol by [bis(trifluoroacetoxy)iodo]benzene, PIFA, in the presence of water and acetonitrile as solvents. No good leaving groups were utilized to insert the alkylthio or alkylamino groups into the quinoline ring. The synthesized compounds will be tested for their anti-inflammatory, anti-bacterial and tuberculostatic inhibition activities at a later stage. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results